In summary, PRS within a population-based PrCa screening programme detected a high proportion of csPrCa (Gleason score ≥7) requiring treatment on national guidelines, compared with PSA or MRI-based screening programmes. The gene discussed is KLK3; the disease is pure red-cell aplasia.